Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer

Palbociclib is a cyclin‐dependent kinase 4/6 inhibitor indicated for treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer in combination with endocrine therapy. We investigated the efficacy and safety of palbociclib in patients enrolled in N...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast J
Main Authors: Gelmon, Karen A., Cristofanilli, Massimo, Rugo, Hope S., DeMichele, Angela M., Joy, Anil A., Castrellon, Aurelio, Sleckman, Bethany, Mori, Ave, Theall, Kathy Puyana, Lu, Dongrui R., Huang, Xin, Bananis, Eustratios, Finn, Richard S., Slamon, Dennis J.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2019
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7155112/
https://ncbi.nlm.nih.gov/pubmed/31448513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/tbj.13516
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados